Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines : an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
Citation
Toback , S , Galiza , E , Cosgrove , C , Galloway , J , Goodman , A L , Swift , P A , Rajaram , S , Graves-Jones , A , Edelman , J , Burns , F , Minassian , A M , Cho , I , Kumar , L , Plested , J S , Rivers , E J , Robertson , A , Dubovsky , F , Glenn , G , Heath , P T & 2019nCoV-302 Study Group 2022 , ' Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines : an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial ' , The Lancet. Respiratory medicine , vol. 10 , no. 2 , pp. 167-179 . https://doi.org/10.1016/S2213-2600(21)00409-4
Rights
© 2022. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/